In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Rhythm Pharmaceuticals Inc’s stock clocked out at $111.73, down -0.12% from its previous closing price of $111.86. In other words, the price has decreased by -$0.12 from its previous closing price. On the day, 0.98 million shares were traded. RYTM stock price reached its highest trading level at $113.07 during the session, while it also had its lowest trading level at $110.33.
Ratios:
To gain a deeper understanding of RYTM’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.53 and its Current Ratio is at 4.75. In the meantime, Its Debt-to-Equity ratio is 1.75 whereas as Long-Term Debt/Eq ratio is at 1.71.
Upgrades & Downgrades
In the most recent recommendation for this company, Citigroup on November 25, 2025, initiated with a Buy rating and assigned the stock a target price of $136.
On July 10, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $97.Goldman initiated its Buy rating on July 10, 2025, with a $97 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 11 ’25 when Cramer Pamela J. sold 3,350 shares for $111.00 per share. The transaction valued at 371,850 led to the insider holds 20,814 shares of the business.
PAMELA CRAMER bought 3,350 shares of RYTM for $350,980 on Dec 11 ’25. On Nov 20 ’25, another insider, Cramer Pamela J., who serves as the Chief Human Resources Officer of the company, sold 3,350 shares for $105.00 each. As a result, the insider received 351,750 and left with 20,814 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RYTM now has a Market Capitalization of 7456419840 and an Enterprise Value of 7300337664. For the stock, the TTM Price-to-Sale (P/S) ratio is 42.77 while its Price-to-Book (P/B) ratio in mrq is 50.07. Its current Enterprise Value per Revenue stands at 41.876 whereas that against EBITDA is -39.513.
Stock Price History:
The Beta on a monthly basis for RYTM is 1.99, which has changed by 0.9932288 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, RYTM has reached a high of $122.20, while it has fallen to a 52-week low of $45.90. The 50-Day Moving Average of the stock is 5.23%, while the 200-Day Moving Average is calculated to be 34.76%.
Shares Statistics:
It appears that RYTM traded 749.97K shares on average per day over the past three months and 1175380 shares per day over the past ten days. A total of 66.68M shares are outstanding, with a floating share count of 62.33M. Insiders hold about 6.60% of the company’s shares, while institutions hold 106.30% stake in the company. Shares short for RYTM as of 1764288000 were 5518605 with a Short Ratio of 7.36, compared to 1761868800 on 5230596. Therefore, it implies a Short% of Shares Outstanding of 5518605 and a Short% of Float of 10.5900005.
Earnings Estimates
A detailed examination of Rhythm Pharmaceuticals Inc (RYTM) is currently in progress, with 11.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.79, with high estimates of -$0.36 and low estimates of -$1.03.
Analysts are recommending an EPS of between -$2.22 and -$3.34 for the fiscal current year, implying an average EPS of -$3.08. EPS for the following year is -$2.62, with 11.0 analysts recommending between -$1.13 and -$3.65.
Revenue Estimates
In. The current quarter, 14 analysts expect revenue to total $55.26M. It ranges from a high estimate of $57.5M to a low estimate of $52M. As of. The current estimate, Rhythm Pharmaceuticals Inc’s year-ago sales were $41.83MFor the next quarter, 14 analysts are estimating revenue of $58.22M. There is a high estimate of $64.8M for the next quarter, whereas the lowest estimate is $50M.
A total of 15 analysts have provided revenue estimates for RYTM’s current fiscal year. The highest revenue estimate was $192.55M, while the lowest revenue estimate was $185M, resulting in an average revenue estimate of $187.97M. In the same quarter a year ago, actual revenue was $130.13MBased on 15 analysts’ estimates, the company’s revenue will be $292.52M in the next fiscal year. The high estimate is $330.48M and the low estimate is $263M.
